학술논문

CYP2U1: An emerging treatable neurometabolic disease with cerebral folate deficiency in 2 Chinese brothers
Document Type
article
Source
Molecular Genetics and Metabolism Reports, Vol 38, Iss , Pp 101023- (2024)
Subject
CYP2U1
Cerebral folate deficiency
Cerebral folate
Folinic acid
Spastic paraplegia 56
5-methyltetrahydrofolate
Medicine (General)
R5-920
Biology (General)
QH301-705.5
Language
English
ISSN
2214-4269
Abstract
With the rapid advancement of medical technologies in genomic and molecular medicine, the number of treatable neurometabolic diseases is quickly expanding. Spastic paraplegia 56 (SPG56), one of the severe autosomal recessive forms of neurodegenerative disorders caused by pathogenic variants in the CYP2U1 gene, has no reported specific targeted treatment yet. Here we report 2 Chinese brothers with CYP2U1 bi-allelic pathogenic variants with cerebral folate deficiency who were treated for over a decade with folinic acid supplement. Patients have remained stable under therapy.